NASDAQ:AKTX Akari Therapeutics (AKTX) Stock Price, News & Analysis $0.99 -0.02 (-1.98%) Closing price 08/8/2025 03:58 PM EasternExtended Trading$1.02 +0.03 (+3.54%) As of 08/8/2025 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Akari Therapeutics Stock (NASDAQ:AKTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Akari Therapeutics alerts:Sign Up Key Stats Today's Range$0.97▼$1.0350-Day Range$0.97▼$1.4252-Week Range$0.85▼$4.22Volume114,538 shsAverage Volume33,997 shsMarket Capitalization$31.86 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingBuy Company Overview Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom. Read More Akari Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScoreAKTX MarketRank™: Akari Therapeutics scored higher than 65% of companies evaluated by MarketBeat, and ranked 336th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAkari Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAkari Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Akari Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioAkari Therapeutics has a P/B Ratio of 1.18. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Akari Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.13% of the float of Akari Therapeutics has been sold short.Short Interest Ratio / Days to CoverAkari Therapeutics has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Akari Therapeutics has recently decreased by 8.02%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAkari Therapeutics does not currently pay a dividend.Dividend GrowthAkari Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.13% of the float of Akari Therapeutics has been sold short.Short Interest Ratio / Days to CoverAkari Therapeutics has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Akari Therapeutics has recently decreased by 8.02%, indicating that investor sentiment is improving significantly. News and Social MediaN/ANews SentimentN/A Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Akari Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $19,120.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders38.10% of the stock of Akari Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 5.06% of the stock of Akari Therapeutics is held by institutions.Read more about Akari Therapeutics' insider trading history. Receive AKTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AKTX Stock News HeadlinesAkari Therapeutics Releases Virtual Investor “What This Means” SegmentJuly 29, 2025 | globenewswire.comAkari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic DriversJuly 23, 2025 | globenewswire.comElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough. | Brownstone Research (Ad)Akari Therapeutics Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand ConferenceJuly 23, 2025 | finance.yahoo.comAkari Therapeutics Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand ConferenceJuly 22, 2025 | globenewswire.comMaxim Group Initiates Coverage of Akari Therapeutics, Plc - Depositary Receipt () (AKTX) with Buy RecommendationJuly 20, 2025 | msn.comAkari Therapeutics initiated with a Buy at MaximJuly 19, 2025 | msn.comPVL: Akari completes Set 3 comeback vs. Capital1 to end group stage on high noteJuly 16, 2025 | msn.comSee More Headlines AKTX Stock Analysis - Frequently Asked Questions How have AKTX shares performed this year? Akari Therapeutics' stock was trading at $1.22 on January 1st, 2025. Since then, AKTX stock has decreased by 18.9% and is now trading at $0.99. How were Akari Therapeutics' earnings last quarter? Akari Therapeutics PLC (NASDAQ:AKTX) posted its quarterly earnings data on Tuesday, March, 31st. The biopharmaceutical company reported ($7.80) earnings per share for the quarter, missing analysts' consensus estimates of ($2.80) by $5.00. When did Akari Therapeutics' stock split? Shares of Akari Therapeutics reverse split on the morning of Thursday, August 17th 2023.The 1-20 reverse split was announced on Thursday, August 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are Akari Therapeutics' major shareholders? Akari Therapeutics' top institutional investors include Omnia Family Wealth LLC (0.19%). View institutional ownership trends. How do I buy shares of Akari Therapeutics? Shares of AKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Akari Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Akari Therapeutics investors own include NVIDIA (NVDA), CymaBay Therapeutics (CBAY), Broadcom (AVGO), Novo Nordisk A/S (NVO), Adobe (ADBE), Meta Platforms (META) and GE Aerospace (GE). Company Calendar Last Earnings3/31/2020Today8/11/2025Next Earnings (Estimated)8/18/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AKTX CIK1541157 Webwww.akaritx.com Phone442080040261Fax646-843-9352Employees9Year FoundedN/APrice Target and Rating Average Price Target for Akari Therapeutics$5.00 High Price Target$5.00 Low Price Target$5.00 Potential Upside/Downside+405.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$19.79 million Net MarginsN/A Pretax MarginN/A Return on Equity-213.59% Return on Assets-65.60% Debt Debt-to-Equity RatioN/A Current Ratio0.16 Quick Ratio0.16 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.84 per share Price / Book1.18Miscellaneous Outstanding Shares32,180,000Free Float19,917,000Market Cap$31.86 million OptionableNot Optionable Beta0.22 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:AKTX) was last updated on 8/11/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akari Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Akari Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.